Haleon Pakistan starts local manufacturing of Panadol 500mg tablets in Sindh
Haleon Pakistan Limited, formerly known as GlaxoSmithKline Consumer Healthcare Pakistan Limited, has commenced manufacturing Panadol 500mg tablets at its Jamshoro facility, marking a shift towards in-house production of the popular pain relief medicine. The company, which is primarily engaged in the manufacturing, marketing, and sale of consumer healthcare and over-the-counter (OTC) health…
Haleon Pakistan Limited, the local entity of GlaxoSmithKline Consumer Healthcare Pakistan, has begun producing Panadol 500mg tablets at its facility in Jamshoro, Sindh. The news was announced in a notice to the Pakistan Stock Exchange (PSX) on Friday. This move follows an investment of around $10 million (~PKR2.8 billion) announced in October 2023, aimed at introducing advanced manufacturing technology and expanding the company's production capacity.
The new Panadol 500mg tablets will have a distinct design, featuring a beacon engraving instead of the traditional 'Panadol' text engraving, though the product's quality and efficacy remain unchanged. This development signifies a major step for Haleon Pakistan Limited in bolstering its in-house manufacturing capabilities and ensuring a steady supply of its products to consumers across Pakistan.
Haleon Pakistan has been investing heavily in recent years to improve its production facilities and diversify its product range. In January 2026, the company allocated £3.58 million (~$4.9 million) to upgrade and expand its Panadol Liquid packaging line, which includes formulations like Children's Panadol Drops, Children's Panadol Liquid, and Panadol Forte Suspension.
The company currently employs 450 individuals across Pakistan and maintains a manufacturing plant in Jamshoro, along with regional sales offices in Multan, Lahore, and Islamabad.
Written by urgent.news from Business Recorder's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
